The EAU20 virtual meeting featured a thematic session looking at the controversy in renal cancer surgery considering the timing and necessity of cytoreductive nephrectomy. Prof. Axel Bex (The Royal Free London NHS Foundation Trust, UK) argued that cytoreductive nephrectomy should only be performed in selected patients after systemic treatment . The counterpoint was provided by Prof. Antonio Finelli (University Health Network, Toronto, Canada) who argued in favour of upfront cytoreductive nephrectomy .
Prof. Bex commenced his debate by stressing that his arguments only apply to patients who require systemic therapy, such as those diagnosed with metastatic renal cell carcinoma (mRCC). There is evidence from 2 trials investigating the role and sequence of cytoreductive nephrectomy. The CARMENA trial randomised 450 patients equally to 1 of 2 arms: either upfront nephrectomy followed by adjuvan...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Immuno-oncology + tyrosine kinase inhibitors in intermediate- and poor-risk mRCC Next Article
New urosepsis data from the SERPENS study »
Table of Contents: EAU 2020
Surgical Techniques and Safety
Prostate Cancer & Imaging
BPH & LUTS
Testis Cancer & Andrology
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.